Abstract
Objectives The current form of severe acute respiratory syndrome called coronavirus disease 2019 (COVID-19) caused by a coronavirus (SARS-CoV-2) is a major global health problem. The aim of our study was to use the official epidemiological data and predict the possible outcomes of the COVID-19 pandemic using artificial intelligence (AI)-based RNNs (Recurrent Neural Networks), then compare and validate the predicted and observed data.
Materials and Methods We used the publicly available datasets of World Health Organization and Johns Hopkins University to create the training dataset, then have used recurrent neural networks (RNNs) with gated recurring units (Long Short-Term Memory – LSTM units) to create 2 Prediction Models. Information collected in the first t time-steps were aggregated with a fully connected (dense) neural network layer and a consequent regression output layer to determine the next predicted value. We used root mean squared logarithmic errors (RMSLE) to compare the predicted and observed data, then recalculated the predictions again.
Results The result of our study underscores that the COVID-19 pandemic is probably a propagated source epidemic, therefore repeated peaks on the epidemic curve (rise of the daily number of the newly diagnosed infections) are to be anticipated. The errors between the predicted and validated data and trends seems to be low.
Conclusions The influence of this pandemic is great worldwide, impact our everyday lifes. Especially decision makers must be aware, that even if strict public health measures are executed and sustained, future peaks of infections are possible. The AI-based predictions might be useful tools for predictions and the models can be recalculated according to the new observed data, to get more precise forecast of the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding This study was supported by the European Union, co-financed by the European Social Fund and European Regional Development Fund [grant No. EFOP-3.6.1-16-2016-00022, ‘Debrecen Venture Catapult Program’ (providing support for SH, LK), by the European Union [EFOP-3.6.2-16-2017-00009 ‘Establishing Thematic Scientific and Cooperation Network for Clinical Research’ (providing support for RG), by the János Bolyai Research Fellowship of the Hungarian Academy of Sciences (providing support for JZ), by the Hungarian Brain Research Program 2.0 under grant number 2017-1.2.1-NKP-2017-00002 and the ED_18-1-2019-0028 providing support for (LK, TB, AT). Research was also supported by the ÚNKP-19-3 - I. New National Excellence Program of the Ministry for Innovation and Technology (AT). Research was supported in part by the project EFOP-3.6.2-16-2017-00015 supported by the European Union, co-financed by the European Social Fund. The role of the funding source The funding sources had no role in the writing of the manuscript of the decision to submit it for publications, no involvement in data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. We have not been paid to write this article by a pharmaceutical company of other agency. Dr. László R. Kolozsvári, the corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data sources are publicly available and described in the methods section.
